At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 399 enrolled
Drug / intervention
Delstrigodrug
Likely dose
Delstrigo 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study
In Brief
A Phase 4 clinical trial evaluating Delstrigo for Hiv. Completed, enrolled 399 participants across 2 sites in 2 countries.
Detailed Summary
Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHiv
CountriesFrance, Spain
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartAug 2020
Primary CompletionJul 2022
TodayJul 2026
First PostedJan 18, 2020
Enrollment StartAug 27, 2020
Primary CompletionJul 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.5 years ago
Interventions
Delstrigodrug
Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) 100 mg doravirine, 300 mg lamivudine,300 mg tenofovir disoproxil fumarate equivalent to 245 mg de tenofovir disoproxil. 1 covered tablet for day .( will be administered 28 days maximum)